Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
Part B of CheckMate 914 did not meet the primary end point of improved DFS for nivolumab versus placebo in patients with localized RCC at high risk of postnephrectomy recurrence.
Authors
- Hernan Javier Cutuli
- Viktor Grünwald (ORCID: https://orcid.org/0000-0003-2083-7687)
- Marc‐Oliver Grimm (ORCID: https://orcid.org/0000-0003-3084-8654)
- Giovanni Schinzari (ORCID: https://orcid.org/0000-0001-6105-7252)
- Bohuslav Melichar (ORCID: https://orcid.org/0000-0002-5474-6866)
- Jeffrey C. Goh (ORCID: https://orcid.org/0000-0003-3103-146X)
- Marine Gross‐Goupil (ORCID: https://orcid.org/0000-0002-3176-4076)
- Carlos Rojas (ORCID: https://orcid.org/0000-0003-0193-3913)
- Brian Shuch (ORCID: https://orcid.org/0000-0003-2065-3570)
- Maximiliano van Kooten Losio
- Paul Russo (ORCID: https://orcid.org/0000-0001-7487-6783)
- Philippe Barthélémy (ORCID: https://orcid.org/0000-0003-3917-0579)
- Julia Spiridigliozzi
- Chung‐Wei Lee (ORCID: https://orcid.org/0000-0002-3573-2506)
- Burçin Şimşek (ORCID: https://orcid.org/0000-0003-2857-6629)
- Abraham Ruiz Garcia
- Robert John Motzer (ORCID: https://orcid.org/0000-0001-6925-2327)
- Axel Bex (ORCID: https://orcid.org/0000-0002-8499-2662)
- Jeffrey A. Sosman (ORCID: https://orcid.org/0000-0002-0650-9698)
- Suresh Nair (ORCID: https://orcid.org/0000-0001-7763-9732)
- Cristina Suárez (ORCID: https://orcid.org/0000-0002-0502-5528)
- Christian Kollmannsberger (ORCID: https://orcid.org/0000-0002-6329-761X)
- Jian Huang (ORCID: https://orcid.org/0000-0002-2409-0878)
- Y Tomita
Institutions
- Northwestern University (US)
- Lehigh Valley Hospital-Pocono (US)
- Memorial Sloan Kettering Cancer Center (US)
- Sun Yat-sen University (CN)
- University of California, Los Angeles (US)
- Fundación Chile (CL)
- Agostino Gemelli University Polyclinic (IT)
- University Medical Center (US)
- The Netherlands Cancer Institute (NL)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Institut de Cancérologie Strasbourg (FR)
- Bristol-Myers Squibb (United States) (US)
- Lehigh Valley Health Network (US)
- Sun Yat-sen Memorial Hospital (CN)
- Oncode Institute (NL)
- Essen University Hospital (DE)
- Vall d'Hebron Hospital Universitari (ES)
- Jena University Hospital (DE)
- Icon (Australia) (AU)
- Vall d'Hebron Institute of Oncology (ES)
- University College London (GB)
- Palacký University Olomouc (CZ)
- Niigata University (JP)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1200/jco.24.00773
- Citations
- 21
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.54